23 results about "Urea derivatives" patented technology

Bisorthohydroxy aromatic urones and their use as curatives and cure accelerators in resin systems particularly epoxy resin systems provide formulations with good outlife, low curing temperatures and desirable glass transition temperatures after curing, they are particularly useful in prepregs used in the production of components for the aerospace and wind turbine industries.

The invention concerns the use of compounds represented by formula (I)as inotropic agents. The compounds of formula (I), which include, as preferred, 1-[(1S)-1-(2,3-dichloro-4-methoxyphenyl)ethyl]-3-methyl-3-[(4R)-1-methyl-3,3-dimethyl-4-piperidyl]-urea and its hydrochloride salt, are herein reported to have a significant inotropic activity on cardiomyocytes from both normal and myocardial infarction-induced heart failure animal models, which makes them useful for treating cardiovascular patients in need thereof. Differently from known inotropic agents, the present compounds are effective on cardiomyocyte contractility without influencing calcium mobilization. Accordingly, they are advantageously free from adverse effects caused by increased calcium concentrations, such as increased oxygen demand, tachycardia, arrhythmia, ischemia, etc. Overall, a new, safe and effective inotropic treatment is thus made available.

This invention relates to a sprayable hair care product in the form of an oil-in-water emulsion, having a pH value of 3.0 to 7.0 at 20°C, comprising at least one water-insoluble oil component (A), at least one nonionic emulsifier (B), at least one nonionic co-emulsifier (C), water, and a buffer system for stabilizing the pH value, wherein the water content is equal to 60 to 90% by weight, component (A) is provided in an amount of 1.5 to 20% by weight, and components (B) and (C) are provided in a total amount of 1 to 12% by weight. The invention is characterized in that adenosine is provided in an amount of 0.01 to 3% by weight, and urea and / or urea derivatives are provided in a total amount of 1.0 to 25% by weight. This invention also relates to a method for preparing a sprayable aqueous formulation of adenosine, wherein an aqueous solution of adenosine is mixed with a finely dispersed emulsion of an oil component (A) such that the formulation contains 1.5 to 20% by weight of the emulsified oil component (A), wherein the average droplet diameter of the oil component (A) (measured using a device based on the principle of quasi-elastic light scattering (Zetasizer Nano ZS, 25°C, square polystyrene cuvette, 12 mm side length (model DTS0012), dilution: 0.025% w / w in water)) is less than 1 μm. During or after preparation and before mixing with the adenosine solution, the emulsion is brought to a phase transition temperature, and urea and / or urea derivatives are added to the resulting mixture at room temperature. This invention also relates to the use of a sprayable aqueous formulation containing adenosine and urea and / or urea derivatives with an ethanol content of less than 18% by weight for cosmetic treatment of the skin, particularly the scalp.

The purpose of the present invention is to provide a method for simultaneously performing concentration and deproteinization of natural rubber latex.　The present invention relates to: a method for concentrating natural rubber latex, the method being characterized by adding a surfactant, urea or a urea derivative, a compound that is selected from the group consisting of hydroxide salts, ammonia and salts thereof, and optionally a polar organic solvent to natural rubber latex, introducing a gas containing at least 0.1-100% by volume of carbon dioxide into the natural rubber latex, leaving the natural rubber latex to stand still so as to separate the natural rubber latex into a cream phase and a serum phase, and recovering the cream phase; and a method for producing a concentrated natural rubber.

A method for producing a carbamic acid salt, including contacting a carbon dioxide-containing mixed gas having a partial pressure of carbon dioxide of 0.001 atm or more and less than 1 atm with an amino group-containing organic compound in the presence of a base in at least one organic solvent selected from the group consisting of an organic solvent having 2 or more and 8 or less carbon atoms, and a method for producing a carbamic acid ester or a urea derivative using the carbamic acid salt.

The invention concerns the use of compounds represented by formula (I)as inotropic agents. The compounds of formula (I), which include, as preferred, 1-[(1S)-1-(2,3-dichloro-4-methoxyphenyl)ethyl]-3-methyl-3-[(4R)-1-methyl-3,3-dimethyl-4-piperidyl]-urea and its hydrochloride salt, are herein reported to have a significant inotropic activity on cardiomyocytes from both normal and myocardial infarction-induced heart failure animal models, which makes them useful for treating cardiovascular patients in need thereof. Differently from known inotropic agents, the present compounds are effective on cardiomyocyte contractility without influencing calcium mobilization. Accordingly, they are advantageously free from adverse effects caused by increased calcium concentrations, such as increased oxygen demand, tachycardia, arrhythmia, ischemia, etc. Overall, a new, safe and effective inotropic treatment is thus made available.

To provide a method for treating a disease mediated by cannabinoid 1 receptor (CB1R).SOLUTION: Heteroaryl and aliphatic analogs of diarylurea-based CB1R allosteric modulators of Formula (I) are provided. Exemplary analogs can provide improved potency and pharmacokinetic properties. Also provided are methods of using the analogs to treat diseases mediated by CB1R, such as substance abuse and adiposity.SELECTED DRAWING: None

The present invention relates to a reducing agent, comprising: a sulfinate of formula I, wherein R1 is H or C1-C6 hydrocarbyl, R2 is C1-C6 hydrocarbyl or M', and M and M' are each independently at least one monovalent cation or a combination with at least one multivalent cation; and optionally, urea or a urea derivative. The reducing agent contains essentially no sulfonic acid or sulfonate. In addition, the present invention relates to a preparation method for the reducing agent. The reducing agent can effectively improve the properties of a polymerization product when used for emulsion polymerization and preparation of a water-soluble polymer.

The invention discloses an alkyne aromatic heterocyclic urea derivative, and particularly relates to a free alkali, an isomer or a pharmaceutically acceptable salt of the derivative and other substance forms. Furthermore, the invention also discloses a preparation method and pharmaceutical application of the alkyne aromatic heterocyclic urea derivative, and the alkyne aromatic heterocyclic urea derivative can be used as an RIPK1 inhibitor for treating diseases related to abnormal expression of a mediated RIPK1 signal channel, including but not limited to tumors, inflammatory diseases or diseases accompanied by inflammatory reactions, autoimmune diseases, neurodegenerative diseases and the like, and has a broad application prospect. The clinical development value is great.

This invention relates to a sprayable hair care product in the form of an oil-in-water emulsion, comprising at least one water-insoluble oil component (A), at least one nonionic emulsifier (B), at least one nonionic co-emulsifier (C), and water, wherein the water content is 60-90% by weight, the content of component (A) is 1.5-20% by weight, and the total content of components (B) and (C) is 1-12% by weight. A key feature of this invention is that the adenosine content is 0.01-3% by weight, and the total content of urea and / or urea derivatives is 1.0-25% by weight. This invention also relates to a method for preparing a sprayable aqueous adenosine formulation, wherein an aqueous adenosine solution is mixed with a finely dispersed emulsion of an oil component (A), the average droplet diameter of which is less than 1 μm (measured using a device based on the principle of semi-elastic light scattering (Zetasizer Nano ZS, 25°C, square polystyrene cuvette, 12 mm side length (model DTS0012), dilution: 0.025% w / w in water)), and the amount of which is such that the formulation contains 1.5 to 20% by weight of the emulsified oil component (A). During or after preparation and before mixing with the adenosine solution, the emulsion is heated to the phase inversion temperature, and urea and / or urea derivatives are added to the resulting mixture at room temperature. This invention also relates to a sprayable aqueous formulation containing adenosine and urea and / or urea derivatives and having an ethanol content of less than 18% by weight for use in cosmetic treatments of the skin, particularly the scalp.

The present application relates to aqueous sprayable hair supplements comprising urea and / or urea derivatives in a total amount of 1.0 to 20 wt.-%, and adenosine in an amount of 0.05 to 3 wt.-%, wherein the hair supplements comprise less than 18 wt.-%, preferably at most 10 wt.-%, in particular at most 5 wt.-%, of ethanol; and the use of a sprayable aqueous formulation containing adenosine and urea and / or urea derivatives with an ethanol content of less than 18 wt.-% for cosmetic treatment of the skin, in particular the scalp.

The invention provides a urea derivative as well as a preparation method and application thereof, and belongs to the field of medicines. The urea derivative provided by the invention has a typical urea structure as a primary pharmacophore of soluble epoxide hydrolase (sEH), can stabilize an endogenous substance epoxy fatty acid with wide physiological activity, and has a very strong inhibition effect on human recombinant sEH; the traditional Chinese medicine composition can regulate the generation of various proinflammatory cytokines, relieve endoplasmic reticulum stress, prevent or reverse endothelial dysfunction and stabilize mitochondria.

A solvent free method for producing chimeric hemicucurbit[n]urils. The method comprises a first step of contacting, under mechanical agitation, at least two different cyclic urea derivatives and a compound that can form methylene bridges in the presence of an acid and templating anions and a second step of aging the products for at least about 30 minutes. The method has a very low process mass intensity (PMI) of 4, making it very attractive from a green chemistry perspective. New chimeric hemicucurbit[n]urils incorporating D-biotin are also described.

The invention discloses a material formula and a forming process of a magnetic control integrated resin plate and an automobile sun visor, and the magnetic control integrated resin plate comprises the following components in parts by weight: 100 parts of bisphenol A epoxy resin, 4-6 parts of dicyandiamide, 80-120 parts of glass fiber cloth, 25-50 parts of silica powder, 30-60 parts of aluminum hydroxide, 30-60 parts of acetone and 0.1-0.5 part of 2-methylimidazole / urea derivative. Through glue preparation, dipping, drying and semi-curing, cutting and overlapping, hot-press forming and magnetizing treatment, the magnetic control integrated resin plate can be formed at a time on a hydraulic machine and vacuum hot-press mold equipment, preparation can be completed through one hot-press procedure, and the production efficiency is high.

The present invention relates to an aqueous, sprayable hair tonic having a pH value of 3.0 to 7.0 at 20°C, comprising urea and / or urea derivatives in a total amount of 1.0 to 20% by weight, adenosine in an amount of 0.05 to 3% by weight, and a buffer system for stabilizing the pH value, wherein the hair tonic comprises less than 18% by weight, preferably not more than 10% by weight, in particular not more than 5% by weight of ethanol; and the use of a sprayable aqueous preparation containing adenosine and urea and / or urea derivatives having an ethanol content of less than 18% by weight for cosmetic treatment of the skin, in particular the scalp.

The present application relates to the field of lithium ion battery electrolyte additives, and particularly relates to a preparation method of an organic film-forming additive, vinylene carbonate. The method comprises the following steps: under the atmosphere of inert gas, (Z)-1,2-dihydroxy ethylene is reacted with a urea derivative under the action of a composite catalyst in a dry organic solvent at 20-100 DEG C for 3-24 hours to generate a crude vinylene carbonate product; then the organic solvent is removed by vacuum distillation in low vacuum, and high-purity vinylene carbonate is obtained by vacuum distillation in high vacuum. The technical scheme of the present application is simple in process, strong in operability, and more safe and environmentally friendly; since the raw material does not contain chlorine, the requirement for equipment is low, no toxic and harmful waste gas and waste solid are generated, and the production cost can be greatly reduced; no water is involved in the reaction process, and the composite catalyst added can also remove the trace water in the solvent and the raw material, which can effectively avoid the hydrolysis of vinylene carbonate, so as to improve the yield, purity and quality of the product, and reduce the moisture content of the product.

The present invention aims to provide a urea derivative having excellent gelling ability, a gelling agent containing the urea derivative as an active ingredient, a cosmetic composition containing the gelling agent, and a method for efficiently producing the urea derivative. [Solution] The urea derivative according to the present invention is characterized by being represented by the following formula (I). TIFF2026112244000006.tif39105 [In the formula, R 1 is C 6-20 This represents an aliphatic hydrocarbon group, where n is an integer between 1 and 6.

The present invention relates to the field of biological medicines. Disclosed are N-tetrazolyl aryl urea derivatives, a preparation method therefor, and the use thereof. The present invention has recently discovered the N-tetrazolyl aryl urea derivatives, and further found that the compounds have an antagonistic activity against bradykinin B1 receptor, so that the compounds can be used as novel bradykinin B1 receptor antagonists and can be further used for treating or preventing related diseases caused by abnormal expression of the bradykinin B1 receptor. In particular, the present invention has recently found that N-tetrazolyl aryl urea derivatives have prevention or treatment effects on corona virus disease 2019, pulmonary edema, diabetes complications, allergic conjunctivitis, etc.